152 related articles for article (PubMed ID: 37634217)
1. Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer.
Id Said B; Soliman H; Moravan V; Myrehaug S; Tseng CL; Detsky J; Sahgal A; Warner E; Jerzak KJ
J Neurooncol; 2023 Sep; 164(2):437-445. PubMed ID: 37634217
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada.
Wang XY; Rosen MN; Chehade R; Sahgal A; Das S; Warner E; Saskin R; Zhang B; Soliman H; Chan KKW; Jerzak KJ
JAMA Netw Open; 2022 Aug; 5(8):e2225424. PubMed ID: 35960523
[TBL] [Abstract][Full Text] [Related]
3. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
5. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
6. Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
Wallace G; Kundalia R; Vallebuona E; Cao B; Kim Y; Forsyth P; Soyano A; Smalley I; Pina Y
Breast Cancer Res; 2024 Mar; 26(1):55. PubMed ID: 38553702
[TBL] [Abstract][Full Text] [Related]
8. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.
Kuksis M; Gao Y; Tran W; Hoey C; Kiss A; Komorowski AS; Dhaliwal AJ; Sahgal A; Das S; Chan KK; Jerzak KJ
Neuro Oncol; 2021 Jun; 23(6):894-904. PubMed ID: 33367836
[TBL] [Abstract][Full Text] [Related]
9. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
10. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.
Berghoff AS; Bago-Horvath Z; Ilhan-Mutlu A; Magerle M; Dieckmann K; Marosi C; Birner P; Widhalm G; Steger GG; Zielinski CC; Bartsch R; Preusser M
Br J Cancer; 2012 Oct; 107(9):1454-8. PubMed ID: 23047551
[TBL] [Abstract][Full Text] [Related]
11. Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China.
Li Y; Li Q; Mo H; Guan X; Lin S; Wang Z; Chen Y; Zhang Y; Zhang D; Chen S; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B
Breast; 2021 Feb; 55():30-36. PubMed ID: 33310633
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study.
Gao YK; Kuksis M; Id Said B; Chehade R; Kiss A; Tran W; Sickandar F; Sahgal A; Warner E; Soliman H; Jerzak KJ
Oncologist; 2021 Nov; 26(11):e1951-e1961. PubMed ID: 34506676
[TBL] [Abstract][Full Text] [Related]
13. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
14. Triple Negative Breast Cancer and Brain Metastases.
Bansal R; Van Swearingen AED; Anders CK
Clin Breast Cancer; 2023 Dec; 23(8):825-831. PubMed ID: 37586926
[TBL] [Abstract][Full Text] [Related]
15. Karnofsky Performance Status (KPS) ≤60 Is Strongly Associated With Shorter Brain-Specific Progression-Free Survival Among Patients With Metastatic Breast Cancer With Brain Metastases.
Freeman M; Ennis M; Jerzak KJ
Front Oncol; 2022; 12():867462. PubMed ID: 35965535
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
17. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
18. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.
Gougis P; Carton M; Tchokothe C; Campone M; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Bachelot T; Hennequin A; Perrin C; Gonçalves A; Uwer L; Eymard JC; Petit T; Mouret-Reynier MA; Chamorey E; Simon G; Saghatchian M; Cailliot C; Le Tourneau C
Breast; 2020 Feb; 49():17-24. PubMed ID: 31675683
[TBL] [Abstract][Full Text] [Related]
19. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
[TBL] [Abstract][Full Text] [Related]
20. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
